A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Hyperphosphatemia Patients on Hemodialysis

In brief

A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Key facts

Study ID

NCT07285291

Run by

Taisho Pharmaceutical Co., Ltd.

People needed

100

Starts

2026-01-09

Expected to finish

2026-12-29

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hyperphosphatemia patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to Visit 1 (Week -3)
• Patients aged >=18 years at the time of obtaining informed consent
• Patients with a serum phosphorus concentration of >= 5.5 mg/dL and < 10.0 mg/dL at Visit 1 (Week -3)
• Patients who have been prescribed at least one phosphate binder within the approved dosage, and the prescribed drug and dosage regimen should have been unchanged during the last 2 weeks prior to Visit 1 (Week -3)

You may not qualify if…

• Patients with confirmed serum intact PTH concentration > 500 pg/mL from Visit 1 (Week -3) to Visit 4 (Week 0)
• Patients who have undergone previous parathyroid intervention (PTx, PEIT, etc.)

Where it is running

• Taisho Pharmaceutical Co., Ltd selected site — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.